Skip to main content
Top
Published in: Pathology & Oncology Research 1/2019

01-01-2019 | Original Article

Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze

Authors: Hatice Toy, Ozlem Etli, Zeliha Esin Celik, Arsenal Sezgin Alikanoglu

Published in: Pathology & Oncology Research | Issue 1/2019

Login to get access

Abstract

This study aimed to evaluate the morphometric measurements in cases with papillary thyroid carcinoma, and determine a cut-off value to support diagnosis. Fifty cases with a diagnosis of papillary thyroid carcinoma (PTC) were included in the study with their Galectine-3, CK-19 and HBME-1 immunohistochemical staining results. Demographic and clinical data gathered from pathology reports, which included demographic information such as patients’ sex, age, macroscopic tumor size, number of tumor focuses; prognostic parameters such as lenfovascular invasion, perineural invasion, thyroid capsule invasion; and results of immunohistochemical CK- 19, Galectin-3 and HBME-1 staining. Longest nuclear diameters of 150 tumor cells and 150 normal thyrocytes of each case were manually measured in an image analysis software, and mean longest nuclear diameters (MLND-TC and MLND-NC), and also tumor cell/normal cell longest nuclear diameter ratio (TC/NC-LNDR) were calculated. MLND-TC was higher than MLND-NC. The cases with higher MLND-TC had increased risk of capsule invasion in case of a negative staining with Galectine-3, HBME-1, or CK-19. When TC/NC-LNDR was high, number of tumor focus tended to be multiple and lymphovascular invasion risk was also increased. Subtypes of PTC were not differed regarding staining patterns. And finally, increased TC/NC-LNDR was associated with increased risk of having poor prognostic factors. The results of this study suggest that MLND-NC, MLND-TC, and TC/NCLNDR are valuable and easy-to-use measures, which can assist routine histology practice.
Literature
1.
go back to reference Cheung CC et al (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14(4):338–342CrossRefPubMed Cheung CC et al (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14(4):338–342CrossRefPubMed
2.
go back to reference Coli A et al (2002) Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 40(1):80–87CrossRefPubMed Coli A et al (2002) Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 40(1):80–87CrossRefPubMed
3.
go back to reference Collan Y (1986) Diagnostic morphometry: relevant background to decision-making in diagnostic histopathology. In: In Science of Form: Proceedings of the First International Symposium for Science on Form 1986, KTK Scientific Publishers, Tokyo, p. 533-542 Collan Y (1986) Diagnostic morphometry: relevant background to decision-making in diagnostic histopathology. In: In Science of Form: Proceedings of the First International Symposium for Science on Form 1986, KTK Scientific Publishers, Tokyo, p. 533-542
4.
go back to reference Isic Dencic T et al (2013) Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol 30(1):362CrossRefPubMed Isic Dencic T et al (2013) Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol 30(1):362CrossRefPubMed
5.
go back to reference Kefeli M et al (2010) Morphometric analysis in cytologic evaluation of papillary thyroid carcinoma. Anal Quant Cytol Histol 32(4):234–238PubMed Kefeli M et al (2010) Morphometric analysis in cytologic evaluation of papillary thyroid carcinoma. Anal Quant Cytol Histol 32(4):234–238PubMed
6.
go back to reference Kumar V, et al (2014) Robbins and cotran pathologic basis of disease – 2014. Online: ElsevierHealth Sciences Kumar V, et al (2014) Robbins and cotran pathologic basis of disease – 2014. Online: ElsevierHealth Sciences
7.
go back to reference Kuzey G (2007) Temel Patoloji, 1st edn. Gunes Kitabevi, İstanbul Kuzey G (2007) Temel Patoloji, 1st edn. Gunes Kitabevi, İstanbul
8.
go back to reference Lee TK et al (1987) The significance of nuclear diameter in the biologic behavior of thyroid carcinomas: a retrospective study of 127 cases. Hum Pathol 18(12):1252–1256CrossRefPubMed Lee TK et al (1987) The significance of nuclear diameter in the biologic behavior of thyroid carcinomas: a retrospective study of 127 cases. Hum Pathol 18(12):1252–1256CrossRefPubMed
9.
go back to reference Lee KJ et al (2011) Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg 35(2):318–323CrossRefPubMed Lee KJ et al (2011) Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg 35(2):318–323CrossRefPubMed
10.
go back to reference Liu Z et al (2014) Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med 7(8):2304–2308PubMedPubMedCentral Liu Z et al (2014) Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med 7(8):2304–2308PubMedPubMedCentral
11.
go back to reference Mai KT et al (2002) Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40(2):133–142CrossRefPubMed Mai KT et al (2002) Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40(2):133–142CrossRefPubMed
12.
go back to reference de Matos PS et al (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47(4):391–401CrossRefPubMed de Matos PS et al (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47(4):391–401CrossRefPubMed
13.
go back to reference Mills SE (2004) Sternberg’s diagnostic surgical pathology, vol 1, 4th edn. Lippincott Williams and Wilkins, Philadelphia Mills SE (2004) Sternberg’s diagnostic surgical pathology, vol 1, 4th edn. Lippincott Williams and Wilkins, Philadelphia
14.
go back to reference Nagashima T, Suzuki M, Nakajima N (1997) Cytologic morphometric approach for the prediction of lymph node involvement in papillary thyroid cancer. Anal Quant Cytol Histol 19(1):49–54PubMed Nagashima T, Suzuki M, Nakajima N (1997) Cytologic morphometric approach for the prediction of lymph node involvement in papillary thyroid cancer. Anal Quant Cytol Histol 19(1):49–54PubMed
15.
go back to reference Saggiorato E et al (2001) Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86(11):5152–5158CrossRefPubMed Saggiorato E et al (2001) Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86(11):5152–5158CrossRefPubMed
16.
go back to reference Salmon I et al (1992) Comparison of morphonuclear features in normal, benign neoplastic thyroid tissue by digital cell image analysis. Anal Quant Cytol Histol 14(1):47–54PubMed Salmon I et al (1992) Comparison of morphonuclear features in normal, benign neoplastic thyroid tissue by digital cell image analysis. Anal Quant Cytol Histol 14(1):47–54PubMed
18.
go back to reference Seok JY, et al (2015) Prognostic value of HBME - 1 in papillary thyroid carcinoma. In: 15th Congress of the Asian Association of Endocrine Surgeons. Seoul, Korea Seok JY, et al (2015) Prognostic value of HBME - 1 in papillary thyroid carcinoma. In: 15th Congress of the Asian Association of Endocrine Surgeons. Seoul, Korea
19.
go back to reference Sorensen FB (1992) Quantitative analysis of nuclear size for objective malignancy grading: a review with emphasis on new, unbiased stereologic methods. Lab Investig 66(1):4–23PubMed Sorensen FB (1992) Quantitative analysis of nuclear size for objective malignancy grading: a review with emphasis on new, unbiased stereologic methods. Lab Investig 66(1):4–23PubMed
20.
go back to reference Wallander M et al (2010) Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. Appl Immunohistochem Mol Morphol 18(3):231–235CrossRefPubMed Wallander M et al (2010) Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. Appl Immunohistochem Mol Morphol 18(3):231–235CrossRefPubMed
21.
go back to reference Weber KB et al (2004) The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–531CrossRefPubMed Weber KB et al (2004) The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–531CrossRefPubMed
22.
go back to reference Wu G et al (2013) Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity? J Int Med Res 41(4):975–983CrossRefPubMed Wu G et al (2013) Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity? J Int Med Res 41(4):975–983CrossRefPubMed
23.
go back to reference Zink D, Fischer AH, Nickerson JA (2004) Nuclear structure in cancer cells. Nat Rev Cancer 4(9):677–687CrossRefPubMed Zink D, Fischer AH, Nickerson JA (2004) Nuclear structure in cancer cells. Nat Rev Cancer 4(9):677–687CrossRefPubMed
Metadata
Title
Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze
Authors
Hatice Toy
Ozlem Etli
Zeliha Esin Celik
Arsenal Sezgin Alikanoglu
Publication date
01-01-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0337-9

Other articles of this Issue 1/2019

Pathology & Oncology Research 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine